Free shipping over €250 · Tracked, discreet delivery in Europe

GLP-1 and glucagon receptor agonist

Survodutide

BI 456906

In clinical trialsNot yet reviewedPeptide

In short: A dual agonist in Phase 3 trials for obesity and fatty liver disease.

Regulatory status

  1. Cosmetic ingredient
  2. Research compound
  3. In clinical trials
  4. Approved medicine

In human clinical trials and not yet approved by the FDA or the EMA. Results to date are from trial populations under medical supervision.

A full research summary for this compound has not been published in the library yet. The status and class above are current.

Common questions

Is Survodutide an approved medicine?

In clinical trials. In human clinical trials and not yet approved by the FDA or the EMA. Results to date are from trial populations under medical supervision.

How much human research is there on Survodutide?

A full research summary for this compound has not been published in the library yet. The status and class above are current.

Does UU supply Survodutide?

No. It appears in the library for reference only, so the field can be read in one place.

More in Gut & weight

Back to the library
  • In trialsuu

    Retatrutide

    GIP, GLP-1 and glucagon receptor agonist

    Early human data
  • Approveduu

    Tirzepatide

    GIP and GLP-1 receptor agonist

    Human trials
  • Approveduu

    Semaglutide

    GLP-1 receptor agonist

    Human trials
  • In trialsuu

    Cagrilintide

    Long-acting amylin analogue

    Human trials
  • Researchuu

    AOD-9604

    Growth hormone fragment

    Mixed evidence
  • Researchuu

    5-Amino-1MQ

    NNMT inhibitor

    Preclinical

The UU library is an educational reference. It is not medical advice, does not make a health claim, and does not tell anyone how to use a compound. UU products are sold for laboratory research use only and are not for human consumption. Regulatory status changes: confirm it with the relevant authority before relying on it.